EMEA-002713-PIP01-19-M02
Key facts
| Active substance |
Etrasimod L-arginine
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0409/2022
|
| PIP number |
EMEA-002713-PIP01-19-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of ulcerative colitis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Arena Pharmaceuticals, Inc.
E-mail: PIP_Enquiries@pfizer.com Tel: +44 (0)1304656607 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|